IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive: This is because there is evidence that IFNα therapy is able to target and sensitize the rare CML stem cell population to subsequent killing by chemotherapy, whereas imatinib is more effective against more differentiated CML progenitors (256, 257).